Seeking Alpha

Amarin (AMRN) says Phase 3 trials for vascepa met primary efficacy endpoints and significantly...

Amarin (AMRN) says Phase 3 trials for vascepa met primary efficacy endpoints and significantly reduced median concentrations of large very-low-density lipoprotein, total LDL, small LDL and total high-density lipoprotein particles and reduced VLDL particle size in patients with very high triglycerides. Shares +1.7% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|